Shirish Gadgeel, MD

Articles

Future Perspectives in ADCs for Treating Advanced NSCLC

February 12th 2024

Dr. Shirish Gadgeel discusses the activity of antibody drug conjugates against brain metastases in non-small cell lung cancer based on emerging data, suggesting superiority over chemotherapy.

Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC

February 9th 2024

Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.

Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC

February 6th 2024

Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.

Dato-DXd for Treating Advanced NSCLC

January 26th 2024

Benjamin Levy, MD, reviews clinical data on Dato-DXd in patients with advanced NSCLC and their practical implications.

T-DXd in HER2 Mutated Advanced NSCLC

January 22nd 2024

Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.

Molecular Testing in Advanced NSCLC

January 18th 2024

Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.

Dr Gadgeel on Adagrasib Monotherapy in KRAS G12C–Mutated NSCLC

September 11th 2023

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

Dr. Gadgeel on CNS Activity Achieved With Adagrasib in KRAS G12C+ NSCLC

August 25th 2022

Shirish M. Gadgeel, MD, discusses the efficacy of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.

Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC

August 23rd 2016

Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.